Perioperative blood loss during total hip arthroplasty (THA) increases patient morbidity, length of stay (LOS), medical resource use (MRU), and costs. Minimizing blood loss may reduce postoperative anemia, the need for blood transfusions, and the increased risk of infections and longer hospital stays associated with blood transfusions. Pharmacologic agents and bipolar sealer devices can minimize perioperative bleeding. A retrospective, comparative cohort study in the US hospital setting was conducted to assess MRU and associated costs and the incidence of transfusion and complications among patients undergoing THA with or without the use of a bipolar sealer. Using a nationwide all-payer hospital administrative database, THA procedures from January 1, 2008, to March 31, 2011, were identified using International Classification of Diseases, Ninth Revision, Clinical Modification procedure code 81.51. The bipolar sealer cohort (n=2683) and matched control cohort (n=2683) had a mean age of 65 years from 38 hospitals. The 2 groups had similar incidences of preoperative anemia and medical comorbidities. Patients in the bipolar sealer group required significantly fewer blood transfusions (21.3% vs 23.8%; P=.0286) and had significantly lower incidence of hematomas (0.2% vs 0.9%; P=.0015) and significantly shorter LOS (2.90 vs 3.31 days; P<.0001) overall. The bipolar sealer group had higher supply costs, which were offset by reduced hospital inpatient room and board and operating room costs; there was no significant difference in total hospital costs between the 2 groups ($18,937 vs $18,734; P=.56). A bipolar sealer decreases postoperative blood transfusions and LOS during primary THA without increasing total hospital costs. 
A s the number of total hip arthroplasties (THAs) in the United States increases, there will be a continued need to control costs and evaluate surgical interventions that minimize complications and promote early hospital discharge and participation in rehabilitation. [1] [2] [3] [4] Postoperative anemia remains one preventable complication that has been associated with prolonged hospital stay and greater resource use, particularly allogeneic blood transfusions. 5, 6 In particular, patients undergoing THA are considered to be at high risk for blood loss and for requiring a transfusion. 6 Transfusion requirements in this patient population have been reported to be as high as 46%, with the majority of patients needing 2 units of blood. 7, 8 Furthermore, blood loss requiring a transfusion is associated with increased risk of infections and increased treatment costs. 5, 6, 9, 10 These patients often require longer hospital and intensive care stays, which have been estimated to be 4.9 days in patients with bleedingrelated complications vs 3.6 days in patients with no bleeding-related complications. 6 This contributes to the higher total hospital costs ($18,973 vs $14,966; P<.001) observed in patients who require transfusions. 6 Methods to reduce costs for THA could have broad implications because THA is one of the most common procedures performed in the United States, with an estimated 285,000 THAs performed annually, and they are costly, with total annual hospital charges estimated at $4.6 billion in 2005 and rising to $19.3 billion in 2015. 2, 4, 11, 12 Different methods to reduce blood loss in THA patients have been investigated. They include antifibrinolytic therapies and energy-based devices that enhance hemostasis by sealing blood vessels at the surgical site. [13] [14] [15] Unlike a traditional electrocautery, a bipolar sealer uses both radiofrequency energy and saline and permanently seals blood vessels through a biomechanical process that transforms and shrinks fibrous collagen in vessel walls. 16 In some recent randomized, controlled trials, a bipolar sealer has been shown to reduce total perioperative blood loss and transfusion requirements in THA compared with electrocautery, 17, 18 although this benefit has not been seen in other studies. 19, 20 There have been no studies that evaluate the aggregate impact of bipolar sealer use in the United States based on evaluation of large-scale hospital databases that may help elucidate usage trends and outcomes in a primarily community-based hospital setting.
The purpose of the current study was to assess the clinical and economic benefits of using a bipolar sealer (Aquamantys System; Medtronic Advanced Energy, Minneapolis, Minnesota) during THA vs a matched cohort without a bipolar sealer based on data from a large-scale administrative database. The authors examined clinical outcomes following primary THA, including (1) blood transfusions, (2) hematoma formation, (3) infections, and (4) medical complications, as well medical resource use (MRU) that included (5) length of stay (LOS), (6) rehospitalization rate, (7) total hospital costs, (8) operating room costs, and (9) surgical supply costs.
Materials and Methods

Study Design
A retrospective, comparative cohort study in the US hospital setting was conducted to assess MRU and associated costs and the incidence of transfusion and complications among patients undergoing THA with or without the use of a bipolar sealer. An all-payer hospital administrative database (Premier's Perspective Comparative Database; Premier, Charlotte, North Carolina), which covers 20% of all inpatients in the United States, was used. This database was compiled through an ongoing cooperative effort of more than 2000 community-based hospitals; it holds data from more than 309 million patient encounters (or 1 in every 5 discharges in the nation) and is a complete census of inpatients and hospitalbased outpatients from geographically diverse hospitals. This database has data from standard hospital discharge files, including patient demographic and disease states, and information on billed services, including medications, laboratories, diagnostics, procedures, and therapeutic services in deidentified patient daily service records.
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Total hip arthroplasty was identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure code 81.51 (total hip replacement; replacement of both femoral head and acetabulum by prosthesis; total reconstruction of hip). Total hip arthroplasty procedures from January 1, 2008, to March 31, 2011, were included in this analysis. The index date is defined as the date of the THA procedure. The pre-index period was defined as the 12 months that preceded the index date (excluding index date) and was used to verify site experience with the bipolar sealer. The index hospitalization was defined as the hospitalization in which the THA procedure was performed and was used to identify demographic characteristics. The post-index period was defined as the 3 months following the index date (excluding the index date). The index hospitalization and post-index period were used to examine the incidence of blood transfusions, complications, and MRU and associated costs during the index hospitalization and subsequent nonelective hospitalizations, respectively. Due to limited pre-index hospitalizations in the study population, the presence of comorbidities was identified using the pre-index period, index hospitalization, and postindex period.
Study Population
A patient was included in the study if he or she had an inpatient procedure code for THA in the principal procedure code field in the procedure file and was 18 years of age or older at the index date. A patient was excluded if the patient's record had $0 costs for room and board or operating room; overall, 5.7% of the patients prior to analysis met this criterion and were excluded. To limit potential bias of the study results due to the learning curve with the use of a bipolar sealer, patients were excluded if the site performed less than 20 THAs using the bipolar sealer in the 12 previous months. The study population consisted of 2 patient cohorts. The case cohort consisted of patients who met all the inclusion/ exclusion criteria where there was documentation in the patient billing file that the bipolar sealer was used during the index hospitalization. The matched (control) cohort included patients who met all the inclusion/exclusion criteria yet did not have documentation in the patient billing file that the bipolar sealer was used during the index hospitalization.
Endpoints
The primary endpoints in this study were procedure-related MRU and associated costs. The MRU endpoints included the following: inpatient stays, inpatient procedures, LOS, emergency room (ER) visits, ER procedures, ER costs, hospital outpatient department visits, hospital outpatient department costs, outpatient procedures, room and board costs, operating room costs, intensive care unit (ICU) costs, medical/surgical supplies costs, blood bank costs, hospitalization costs, and total costs. All costs were updated to 2011 US dollars (USD) using the medical care component of the Consumer Price Index.
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The secondary endpoints included discharge status and the incidence of procedure-related blood transfusions (ICD-9-CM codes 99.00, 99.02, 99.04, and V58.2), transfusion-related complications (ICD-9-CM codes 518. 7 
Statistical Analysis
To limit case selection bias, each case cohort patient was paired with 1 matched cohort patient by a propensity score matching algorithm, based on the patient's demographic characteristics, including age, sex, and race; hospital at which the index procedure was performed (site); coexisting clinical characteristics (ie, comorbidities); primary payer; and year the index procedure was performed. Because site was a factor in the matching algorithm, only those sites in which bipolar sealer was used were included in the analysis. The nearest available Mahalanobis metric matching within calipers defined by the propensity score technique was used to pair case cohort patients to matched cohort patients. This technique has been noted as the best propensity score matching method to reduce bias. 23 As suggested by Rosenbaum and Rubin, 23 a caliper size equal to one-quarter of a standard deviation of the logit of the propensity score was used. To evaluate the performance of the matching, the matching variables were compared between cohorts in the pre-match and post-match populations.
Analyses were performed using SAS version 9.1 or higher statistical software (SAS Institute, Cary, North Carolina). Analyses compared the case and matched control groups, specifically for the index hospitalization, subsequent nonelective hospitalizations, and overall (index plus subsequent nonelective). Descriptive statistics were calculated to summarize the results of the analyses. The number of patients, mean, median, SD, minimum, and maximum values were calculated for continuous variables, and the number of respondents and percentages were calculated for categorical variables. Statistical tests to determine significant differences were conducted to compare the 2 study cohorts. Continuous variables were compared using Student's t test or Wilcoxon's test, as appropriate. Categorical variables were compared using Pearson's chi-square test or Fisher's exact test.
results
Prior to the propensity score matching, a total of 13,625 patients met the inclusion/exclusion criteria (3281 case and 10,344 control patients). The yield of the match was high in that 81.8% (2683) of the case patients matched, which resulted in a total of 5366 THA patients with a mean age of 65 years from 38 sites. There was no significant difference in the preoperative incidence of anemia between the 2 groups (43 vs 44%; P=.30) or any medical comorbidity ( Table 1 ). The only significant difference observed was patient insurance status (P=.0043) ( Table  1) .
The incidence of blood transfusions was significantly lower for the case cohort compared with the matched cohort overall (21.3% vs 23.8%; P=.0286) ( Table 2) , during the index hospitalization (21.2% vs 23.5%; P=.0457), and during subsequent nonelective hospitalizations (15.4% vs 77.8%; P=.0027).
The incidence of hematoma was also significantly lower for the case cohort compared with the matched cohort overall (0.2% vs 0.9%; P=.0015) and during the index hospitalization (0.2% vs 0.8%; P=.0024). The incidences of other infections and complications were similar between the case cohort and matched cohort overall and for index hospitalization and subsequent nonelective hospitalizations (P>.05) ( Table 2) .
Average LOS for the case cohort was significantly less than the matched cohort overall (2.90 vs 3.31 days; P<.0001) and for index hospitalizations (2.86 vs 3.26 days; P<.0001). The difference in the length of subsequent nonelective hospitalizations was not significant (7.23 vs 0.78; P=.098). Although the rate of subsequent nonelective hospitalizations (0.5% vs 14) . No ER, hospital outpatient department, or rehabilitation visits occurred within 3 months of the index hospitalization at the same facility.
Total mean hospital costs were similar between the case and matched cohorts ($18,937 vs $18,734, respectively; P=.56) ( Table 3 ). The case cohort had significantly lower mean room and board costs for both the index and subsequent nonelective hospitalizations compared with the matched cohort (index hospitalization: $2,489 vs $2,897; P<.0001; subsequent nonelective hospitalizations: $6,322 vs $6,765; P=.012) ( Table  3 ). Operating room costs (which are a surrogate measure for operating room time) for the index hospitalization also were significantly less for the case cohort compared with the matched cohort ($3,307 vs $3,374; P=.0001). However, medical/surgical supplies costs for the index hospitalization were significantly higher for the case cohort compared with the matched cohort ($1,521 vs $845; P<.0001). Total mean blood product costs for the index hospitalizations for the case cohort were lower compared with the matched cohort but were not statistically significant ($434 vs $502; P=.12) (Figure) .
Discharge status differed significantly between the case cohort and matched cohort (P<.0001; Table 1 ); more patients in the case cohort were discharged to home or self-care (33.6% vs 24.1%) and fewer were discharged to home health organizations (37.2% vs 41.4%) and skilled nursing facilities (23.6% vs 26.8%) compared with the matched cohort ( Table 1) .
discussion
This study examined the perioperative clinical outcomes and hospital costs during THA associated with vs without the use of the bipolar sealer in using a nationwide hospital administrative database. The results of this study demonstrate that patients undergoing THA with the bipolar sealer had significantly fewer blood transfusions, fewer hematomas, shorter lengths of stay, and lower operating room costs but had higher surgical supply costs. The observed mean difference of $676 in the medical/surgical supplies costs is likely due to the incremental cost of the bipolar sealer disposable hand pieces. Overall, the total hospital costs for both groups were similar.
There were several limitations to this study. The use of a national database may have biased the results slightly by not providing an accurate cross-section of the general THA patient population. However, this database is based on prospectively collected data and represents 20% of all hospital discharges; thus, any confounders in sampling are likely negligible. Another potential limitation is that one group of patients could have had lower baseline hemoglobin levels, which was addressed by matching on preoperative anemia and resulted in a similar prevalence of preoperative anemia in both groups. Other secondary factors that may have affected clinical outcomes such as medical comorbidities were also controlled for between the 2 matched groups. One further limitation may be the results of the propensity score matching, where a significant difference was observed between the 2 groups based on insurance .7595
Total subsequent nonelective hospitalization cost status. Although there was a statistical difference, it is unlikely this has clinical relevance because the magnitude of the difference between the distributions for insurance status was small (eg, 43% of patients in the case cohort had private insurance vs 42% in the matched cohort) and patients were well matched on all demographic variables. Due to limitations in the database, the authors were also not able to determine the eligibility criteria that surgeons used to decide whether to use a bipolar sealer. In many situations, a surgeon may be inclined to use this device in more complex cases; thus, if there was any selection bias and heterogeneity, it may have contributed to underestimating the benefits of the bipolar sealer. The database also does not include the number of blood units transfused, nor does it capture readmissions to hospitals other than those in which the index THA procedures were performed. Nevertheless, the data used in this study represent a robust set of data for a large sample of THA patients that enabled the evaluation of important clinical and economic outcomes, such as the incidence of complications, infections and blood transfusions, MRU, and associated costs across time and practice settings. The reduction in blood loss and transfusion requirements is an important clinical outcome in THA. In this study, patients undergoing THA with the bipolar sealer had a significantly lower transfusion rate compared with those without the bipolar sealer (21.3% vs 23.8%; P=.0286). This finding is consistent with results from 2 prospective, randomized studies of the bipolar sealer vs electrocautery in THA, which reported less blood loss when a bipolar sealer was used. 17 Marulanda et al 17 reported a significantly lower transfusion rate among patients undergoing THA with the bipolar sealer compared with electrocautery (20.0% vs 52.0%; P=.005), although the overall transfusion rate among their group (52.0%) was higher compared with the current study (23.8%), which could possibly be explained by the definition of the control groups between the 2 studies. The control cohort in the current study included patients with standard electrocautery or another hemostatic device without the bipolar sealer, whereas Marulanda et al's 17 control group included only electrocautery. Furthermore, the authors reported that more patients in the electrocautery group had a body mass index (BMI) of 30 kg/m 2 or higher compared with the bipolar sealer group, 17 and higher BMI has been found to be correlated with greater transfusion requirements. 24 Other studies by Barsoum et al 19 and Zeh et al 25 reported no significant differences in blood loss or transfusion requirements in THA with the bipolar sealer vs standard electrocautery. However, these single-center studies applied narrower inclusion/exclusion criteria compared with the current study by excluding patients with bleeding disorders and hemoglobin levels below 11.5 g/dL or hematocrit less than 35%.
Anemia has been shown to be correlated with increased blood loss and transfusion requirements. [26] [27] [28] The study by Barsoum et al 19 also consisted of a younger population, with a mean age of 55 years, compared with 65 years in the current study. Previous studies indicate that advancing age is a risk factor for increased transfusion rates and complications in THA. 29, 30 Another study using Premier data from July 1, 2003, through June 30, 2004 , also assessed the use and costs of blood transfusions during hip surgery. Blanchette et al 5 reported that the rate of blood transfusions in THA procedures was 12.57%, which is roughly half the rate of blood transfusions reported in the current analysis that used Premier data from January 1, 2008, to March 31, 2011. The difference in blood transfusion rates may reflect changes in clinical practice patterns over time, differences in the specific codes used to identify blood transfusions, and/or increased Premier hospital membership through the years. Further, a recent study by Keeney et al 31 reported that readmission rates within 90 days after THA for bleeding and wound-and arthroplasty-related complications ranged from 3.0% for cardiac-related diagnoses to 22.8% for bleeding and joint-specific diagnoses based on an institutional readmission database. The current study found that the rate of nonelective rehospitalizations within 3 months after the index THA procedure was 0.5% and 0.7% among patients undergoing THA with and without the bipolar sealer, respectively. Although this rehospitalization rate is substantially less than that reported by Keeney et al, 31 the current study found that these subsequent nonelective rehospitalizations were associated with considerable costs, and the use of the bipolar sealer was associated with significantly lower incidence of blood transfusions in these rehospitalizations when compared with THAs without the bipolar sealer (15.4% vs 77.8%; P=.003). The lower readmission rates observed in the current study could be explained, in part, given that the Premier hospital administrative database does not capture readmissions to hospitals other than the hospital in which the index THA procedure was performed. In addition, Keeney et al 31 represents a single institution's experience, whereas the current study represents the experience across nearly 40 institutions in the United States, which suggests that the current findings may reflect patient care more broadly.
Although the current study demonstrated that patients undergoing THA with the bipolar sealer had a significantly shorter LOS and approximately half of the study population was of working age, indirect costs such as missed work days and lost productivity could not be analyzed due to the lack of data. The impact on LOS has been increasingly understood to affect total health care costs and bed availability. In an analysis of Danish Arthroplasty Register, Husted et al 32 also demonstrated that shorter hospital stays were associated with greater patient satisfaction and better clinical outcomes. In addition, although the bipolar sealer patients were more frequently discharged to home instead of to extended-care facilities, the costs associated with the extended-care facilities (eg, home health or skilled nursing facility) are not captured in the Premier database. Therefore, the current results likely underestimate the overall societal cost savings associated with the bipolar sealer device.
conclusion
This study's results demonstrated that, among patients undergoing THA, the bipolar sealer device is associated with reduced incidence of hematomas, reduced rates of blood transfusion, shorter LOS, and less post-acute care while remaining cost neutral when compared with THAs without the bipolar sealer device. Recent US health care reform legislation focuses on improving quality of care and reducing costs, for example, by preventing hospital-based infections and readmissions. The economic burden of THA in the United States is substantial and highlights the need for blood-sparing methods that help prevent blood transfusions and reduce health care expenditures. However, given the current controversy of the efficacy of bipolar sealer in the literature, further large-scale studies will be required to fully evaluate the role this technology may have in primary THA.
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